Literature DB >> 22910437

Clinical translation of cell-based pharmacogenomic discovery.

N J Cox1, E R Gamazon, H E Wheeler, M E Dolan.   

Abstract

The use of cell-based models has emerged as a promising means to discover and validate pharmacologic phenotype-genotype relationships. The availability of large-scale genome studies in both human and model systems is now allowing us an unprecedented opportunity to understand how well cell-based models identify clinically relevant genetic variants associated with drug response and toxicity. Here we review these studies and the emerging translational information.

Entities:  

Mesh：

Year:  2012        PMID： 22910437      PMCID： PMC3664667          DOI： 10.1038/clpt.2012.115

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  5 in total

1.  Genetic architecture of transcript-level variation in humans.

Authors:  Shiwei Duan; R Stephanie Huang; Wei Zhang; Wasim K Bleibel; Cheryl A Roe; Tyson A Clark; Tina X Chen; Anthony C Schweitzer; John E Blume; Nancy J Cox; M Eileen Dolan
Journal:  Am J Hum Genet       Date:  2008-04-24       Impact factor: 11.025

2.  Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci.

Authors:  Eric R Gamazon; R Stephanie Huang; Nancy J Cox; M Eileen Dolan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-04       Impact factor: 11.205

3.  Gene expression in skin and lymphoblastoid cells: Refined statistical method reveals extensive overlap in cis-eQTL signals.

Authors:  Jun Ding; Johann E Gudjonsson; Liming Liang; Philip E Stuart; Yun Li; Wei Chen; Michael Weichenthal; Eva Ellinghaus; Andre Franke; William Cookson; Rajan P Nair; James T Elder; Gonçalo R Abecasis
Journal:  Am J Hum Genet       Date:  2010-12-10       Impact factor: 11.025

Review 4.  Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation.

Authors:  Heather E Wheeler; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2012-01       Impact factor: 2.533

5.  Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.

Authors:  Heather E Wheeler; Eric R Gamazon; Claudia Wing; Uchenna O Njiaju; Chidiamara Njoku; Robert Michael Baldwin; Kouros Owzar; Chen Jiang; Dorothy Watson; Ivo Shterev; Michiaki Kubo; Hitoshi Zembutsu; Eric P Winer; Clifford A Hudis; Lawrence N Shulman; Yusuke Nakamura; Mark J Ratain; Deanna L Kroetz; Nancy J Cox; Mary Eileen Dolan
Journal:  Clin Cancer Res       Date:  2012-11-30       Impact factor: 12.531
  5 in total
  16 in total

1.  Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science.

Authors:  M Eileen Dolan; Michael L Maitland; Peter H O'Donnell; Yusuke Nakamura; Nancy J Cox; Mark J Ratain
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

2.  Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy.

Authors:  Masaaki Komatsu; Heather E Wheeler; Suyoun Chung; Siew-Kee Low; Claudia Wing; Shannon M Delaney; Lidija K Gorsic; Atsushi Takahashi; Michiaki Kubo; Deanna L Kroetz; Wei Zhang; Yusuke Nakamura; M Eileen Dolan
Journal:  Clin Cancer Res       Date:  2015-05-26       Impact factor: 12.531

Review 3.  Combining genetic and nongenetic biomarkers to realize the promise of pharmacogenomics for inflammatory diseases.

Authors:  Joseph C Maranville; Anna Di Rienzo
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

Review 4.  Cancer pharmacogenomics: early promise, but concerted effort needed.

Authors:  Howard L McLeod
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

5.  Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.

Authors:  Heather E Wheeler; Eric R Gamazon; Claudia Wing; Uchenna O Njiaju; Chidiamara Njoku; Robert Michael Baldwin; Kouros Owzar; Chen Jiang; Dorothy Watson; Ivo Shterev; Michiaki Kubo; Hitoshi Zembutsu; Eric P Winer; Clifford A Hudis; Lawrence N Shulman; Yusuke Nakamura; Mark J Ratain; Deanna L Kroetz; Nancy J Cox; Mary Eileen Dolan
Journal:  Clin Cancer Res       Date:  2012-11-30       Impact factor: 12.531

6.  Lymphoblastoid cell lines models of drug response: successes and lessons from this pharmacogenomic model.

Authors:  J Jack; D Rotroff; A Motsinger-Reif
Journal:  Curr Mol Med       Date:  2014       Impact factor: 2.222

7.  Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes?

Authors:  Amy L Stark; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2013-04       Impact factor: 2.533

8.  Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses.

Authors:  Heather E Wheeler; Anna González-Neira; Guillermo Pita; Julio-Cesar de la Torre-Montero; Rosario Alonso; Luis A Lopez-Fernandez; Emilio Alba; Miguel Martín; M Eileen Dolan
Journal:  Pharmacogenet Genomics       Date:  2014-05       Impact factor: 2.089

9.  Genetic and epigenetic variants contributing to clofarabine cytotoxicity.

Authors:  Michael T Eadon; Heather E Wheeler; Amy L Stark; Xu Zhang; Erika L Moen; Shannon M Delaney; Hae Kyung Im; Patrick N Cunningham; Wei Zhang; M Eileen Dolan
Journal:  Hum Mol Genet       Date:  2013-05-29       Impact factor: 6.150

Review 10.  Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.

Authors:  Lois B Travis; Sophie D Fossa; Howard D Sesso; Robert D Frisina; David N Herrmann; Clair J Beard; Darren R Feldman; Lance C Pagliaro; Robert C Miller; David J Vaughn; Lawrence H Einhorn; Nancy J Cox; M Eileen Dolan
Journal:  J Natl Cancer Inst       Date:  2014-03-12       Impact factor: 13.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.